Research Papers:

Ras inhibition by FTS attenuates brain tumor growth in mice directly and by enhancing reactivity of cytotoxic lymphocytes

Elizabeta Aizman, Adi Mor, Ayelet Levy, Jacob George and Yoel Kloog _

PDF  |  HTML  |  How to cite

Oncotarget. 2012; 3:144-157. https://doi.org/10.18632/oncotarget.420

Metrics: PDF 2456 views  |   HTML 3170 views  |   ?  


Elizabeta Aizman1, Adi Mor1, Ayelet Levy1, Jacob George2 and Yoel Kloog1

1Department of Neurobiology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, 69978 Tel Aviv

2Department of Cardiology, Kaplan Medical Center, Rehovot, Israel

Received: January 2, 2012; Accepted: January 29, 2012; Published: February 7, 2012;

Keywords: Ras, Glioblastoma, CTL, FTS, Salirasib


Dr. Yoel Kloog, email:


One of the concerns in targeted drug therapy is that the inhibition of receptors and signaling molecules in tumor cells may also affect similar components in the tumor microenvironment or in the immune system, with undefined consequences for inhibition of tumor growth. Thus, in addition to its antitumor activity in mice and humans, the Ras inhibitor salirasib (S-farnesylthiosalicylic acid, FTS) also exhibits anti-inflammatory activity. Here we show three antitumor effects of FTS in immune-competent mice with subcutaneous or intracranial tumors. First, FTS exhibited antitumor activity in immune-competent, intracranial tumor-bearing mice and increased their survival relative to tumor-bearing immune-compromised mice. Second, FTS induced an increase in regulatory T cells in mouse splenocytes, but the inhibitory effects of FTS on tumor growth were not affected by these Foxp3+ T lymphocytes. Third, FTS increased antitumor T-cell reactivity by downregulating Foxp3. This caused TGF-β-dependent sensitization of the tumor to the immune system.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 420